Purinergic receptor P2Y1 and Purinergic receptor P2Y12 (P2Y1/P2Y12)

The P2Y1 and P2Y12 receptors are G protein-coupled receptors (GPCRs) expressed on the surface of platelets that mediate the response to adenosine diphosphate (ADP), a key agonist in platelet activation (Source: UniProt P47900, Q9H244). P2Y1 is coupled to the Gq protein and initiates platelet shape change and transient aggregation by mobilizing intracellular calcium (Source: PubMed 11311135). P2Y12 is coupled to the Gi protein and is essential for amplifying and sustaining the aggregation response by inhibiting adenylyl cyclase and activating the phosphoinositide 3-kinase (PI3K) pathway (Source: StatPearls NBK538152). Together, these receptors are critical for the formation and stabilization of a hemostatic plug or thrombus at sites of vascular injury. In pathological states, their overactivation leads to arterial thrombosis, contributing to myocardial infarction and stroke (Source: NIH PMC3108295). Consequently, the P2Y12 receptor is a primary therapeutic target for antiplatelet drugs like clopidogrel, prasugrel, and ticagrelor, which are standard of care for patients with acute coronary syndromes or those undergoing percutaneous coronary intervention (Source: Frontiers in Pharmacology 13:854114). While P2Y1 is also a potential target, clinical focus remains largely on P2Y12 due to its dominant role in thrombus stabilization and the success of existing inhibitors.

Other names

P2Y purinoceptor 1P2Y purinoceptor 12ADP receptorsP2RY1P2RY12P2Y1RP2Y12RPlatelet ADP receptors

Antagonism of ADP-induced platelet activation. P2Y12 inhibitors block the Gi-coupled pathway, preventing inhibition of adenylyl cyclase and activation of PI3K/Akt. P2Y1 inhibitors block the Gq-coupled pathway, preventing calcium mobilization and shape change.